![Henning R. Stennicke](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Henning R.
Stennicke is currently the Chief Scientific Officer at Freeline Therapeutics Holdings Plc since 2022.
Prior to this, he worked as the Project Vice President-Global Development Biopharm at Novo Nordisk A. He holds an MBA from the Technical University of Denmark and a graduate degree from the University of Copenhagen.
| Companies | Position | Start |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 01/03/2022 |
| Companies | Position | End |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 4 |
|---|---|
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Technical University of Denmark
 Technical University of Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
Choose MarketScreener 
